SEC demonstrated high retention rates after 5 years in pts with PsA and r-axSpA in this real-world study. Reasons for stopping SEC: lack of efficacy pt decision lost to ffup AEs Reassuring data on SECs position in the treatment of PsA/AS. @Rheumnow #ACR24 abs2344 https://t.co/zECEsheQIi